





Recent and planned developments in pharmaceutical policies 2018

Special topic: national incentives and derogatory procedures for orphan medicines

CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
No change	No change
OTHERS CHANGES	
extension of the e-prescription system to medical aids is in planning phase	

SPECIAL TOPIC: National Incentives and Derogatory Procedures for Orphan Medicines

Existing incentives:

- Research and development: NO
- Market access prior to marketing authorisation: NO
- Availability: patient organisation for rare diseases
- Place of treatment: Centres of expertise exist
- Pricing: no special pricing rules for orphan medicinal products
- Funding: NEAK has dedicated budget for orphan medicinal products
- Reimbursement: no special rules for orphan medicinal products; 100% reimbursement (1 € co-payment)
- Assessment of orphans: no special assessment for orphan medicinal products